Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.
The recognition that atherosclerosis represents an inflammatory disease has begun to shift interest towards novel therapies that could specifically target the underlying inflammatory component of atherogenesis. Like low-density lipoprotein, an ideal new drug target would be a modifiable plasma risk factor that not only reflects the ongoing inflammatory process but also actively promotes it. Lipoprotein-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new risk factor that may have the potential to fulfil these requirements.
Macphee
C H
CH
Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK. Colin_H_Macphee@sbphrd.com
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000818:Animals; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000201:enzymology / Q000209:etiology* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006801:Humans; D007239:Infections / Q000150:complications / Q000378:metabolism; D007249:Inflammation / Q000201:enzymology / Q000209:etiology* / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008244:Lysophosphatidylcholines / Q000378:metabolism; D010084:Oxidation-Reduction; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D054467:Phospholipases A2; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D012307:Risk Factors
D015415:Biomarkers; D004791:Enzyme Inhibitors; D005230:Fatty Acids, Nonesterified; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D010972:Platelet Activating Factor; D010741:Phospholipases A; D054467:Phospholipases A2; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase